Previous close | 71.81 |
Open | 71.61 |
Bid | 72.26 x 100 |
Ask | 92.90 x 200 |
Day's range | 71.61 - 72.80 |
52-week range | 45.50 - 84.89 |
Volume | |
Avg. volume | 966,926 |
Market cap | 7.65B |
Beta (5Y monthly) | 1.01 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.46 |
Earnings date | 07 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 91.91 |
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Tuesday, May 7, 2024, to provide a corporate update and discuss details of the Company's financial results for the quarter ended March 31, 2024. To attend the live con
Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.